196 related articles for article (PubMed ID: 35714574)
21. Intraoperative Electron Beam Radiation Therapy (IOERT) Versus High-Dose-Rate Intraoperative Brachytherapy (HDR-IORT) in Patients With an R1 Resection for Locally Advanced or Locally Recurrent Rectal Cancer.
Voogt ELK; van Rees JM; Hagemans JAW; Rothbarth J; Nieuwenhuijzen GAP; Cnossen JS; Peulen HMU; Dries WJF; Nuyttens J; Kolkman-Deurloo IK; Verhoef C; Rutten HJT; Burger JWA
Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1032-1043. PubMed ID: 33567303
[TBL] [Abstract][Full Text] [Related]
22. Oncologic outcomes after radical surgery following preoperative chemoradiotherapy for locally advanced lower rectal cancer: abdominoperineal resection versus sphincter-preserving procedure.
Kim JS; Hur H; Kim NK; Kim YW; Cho SY; Kim JY; Min BS; Ahn JB; Keum KC; Kim H; Sohn SK; Cho CH
Ann Surg Oncol; 2009 May; 16(5):1266-73. PubMed ID: 19224287
[TBL] [Abstract][Full Text] [Related]
23. Treatment and survival of locally recurrent rectal cancer: A cross-sectional population study 15 years after the Dutch TME trial.
Detering R; Karthaus EG; Borstlap WAA; Marijnen CAM; van de Velde CJH; Bemelman WA; Beets GL; Tanis PJ; Aalbers AGJ;
Eur J Surg Oncol; 2019 Nov; 45(11):2059-2069. PubMed ID: 31230980
[TBL] [Abstract][Full Text] [Related]
24. Can increasing the dose of radiation by HDR brachytherapy boost following pre operative chemoradiotherapy for advanced rectal cancer improve surgical outcomes?
Sun Myint A; Mukhopadhyay T; Ramani VS; Perkins K; Snee AJ; Jelley F; Wong H; Lee CD
Colorectal Dis; 2010 Aug; 12 Suppl 2():30-6. PubMed ID: 20618365
[TBL] [Abstract][Full Text] [Related]
25. A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer - GRECCAR 15 trial protocol.
Denost Q; Frison E; Salut C; Sitta R; Rullier A; Harji D; Maillou-Martinaud H; Rullier E; Smith D; Vendrely V;
Colorectal Dis; 2021 Jul; 23(7):1909-1918. PubMed ID: 33843133
[TBL] [Abstract][Full Text] [Related]
26. Radical resection after IORT-containing multimodality treatment is the most important determinant for outcome in patients treated for locally recurrent rectal cancer.
Dresen RC; Gosens MJ; Martijn H; Nieuwenhuijzen GA; Creemers GJ; Daniels-Gooszen AW; van den Brule AJ; van den Berg HA; Rutten HJ
Ann Surg Oncol; 2008 Jul; 15(7):1937-47. PubMed ID: 18389321
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemoradiotherapy].
Sun Y; Chi P; Lin H; Lu X; Huang Y; Xu Z; Huang S; Ye D; Wang X
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Apr; 19(4):436-41. PubMed ID: 27112480
[TBL] [Abstract][Full Text] [Related]
28. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
29. [Surgical treatment outcomes of multimodality therapy for locally recurrent rectal cancer].
Koyama M; Murata A; Sakamoto Y; Morohashi H; Hasebe T; Saito T; Awatsu A; Abo E; Terui K; Hakamada K
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1459-61. PubMed ID: 25731218
[TBL] [Abstract][Full Text] [Related]
30. Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: A Systematic Review and Metaanalysis of Oncological and Operative Outcomes.
Kong JC; Soucisse M; Michael M; Tie J; Ngan SY; Leong T; McCormick J; Warrier SK; Heriot AG
Ann Surg Oncol; 2021 Nov; 28(12):7476-7486. PubMed ID: 33891203
[TBL] [Abstract][Full Text] [Related]
31. Comparative Outcomes of Preoperative Chemoradiotherapy and Selective Postoperative Chemoradiotherapy in Clinical Stage T3N0 Low and Mid Rectal Cancer.
Lin Y; Lin H; Xu Z; Zhou S; Chi P
J Invest Surg; 2019 Nov; 32(7):679-687. PubMed ID: 30215538
[No Abstract] [Full Text] [Related]
32. Stepwise neoadjuvant chemoradiotherapy in the management of mid-low locally advanced rectal cancer.
Zhang YX; Liu HY; Jiang B; Wang WY; Wang HB; Lu YJ
Eur J Surg Oncol; 2020 Mar; 46(3):410-414. PubMed ID: 31627933
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant chemo-radiotherapy for cT3N0 rectal cancer: any benefit over upfront surgery? A propensity score-matched study.
Sorrentino L; Guaglio M; Battaglia L; Bonfanti G; Vitellaro M; Bianchi AC; Milione M; Belli F
Int J Colorectal Dis; 2019 Dec; 34(12):2161-2169. PubMed ID: 31741026
[TBL] [Abstract][Full Text] [Related]
34. [Short-term outcome of programmed cell death protein1 (PD-1) antibody combined with total neoadjuvant chemoradiotherapy in the treatment of locally advanced middle-low rectal cancer with high risk factors].
Li YJ; Zhang L; Dong QS; Cai Y; Zhang YZ; Wang L; Yao YF; Zhang XY; Li ZW; Li YH; Sun YS; Wang WH; Wu AW
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):998-1007. PubMed ID: 34823301
[No Abstract] [Full Text] [Related]
35. PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.
Sclafani F; Brown G; Cunningham D; Wotherspoon A; Tait D; Peckitt C; Evans J; Yu S; Sena Teixeira Mendes L; Tabernero J; Glimelius B; Cervantes A; Thomas J; Begum R; Oates J; Chau I
Ann Oncol; 2016 Aug; 27(8):1557-65. PubMed ID: 27217542
[TBL] [Abstract][Full Text] [Related]
36. Evolution of clinical nature, treatment and survival of locally recurrent rectal cancer: Comparative analysis of two national cross-sectional cohorts.
van Geffen EGM; Langhout JMA; Hazen SJA; Sluckin TC; van Dieren S; Beets GL; Beets-Tan RGH; Borstlap WAA; Burger JWA; Horsthuis K; Intven MPW; Aalbers AGJ; Havenga K; Marinelli AWKS; Melenhorst J; Nederend J; Peulen HMU; Rutten HJT; Schreurs WH; Tuynman JB; Verhoef C; de Wilt JHW; Marijnen CAM; Tanis PJ; Kusters M; On Behalf Of The Dutch Snapshot Research Group
Eur J Cancer; 2024 May; 202():114021. PubMed ID: 38520925
[TBL] [Abstract][Full Text] [Related]
37. The efficiency of
Uemura M; Ikeda M; Handa R; Danno K; Nishimura J; Hata T; Takemasa I; Mizushima T; Yamamoto H; Sekimoto M; Doki Y; Eguchi H
BMC Cancer; 2021 Oct; 21(1):1132. PubMed ID: 34674666
[TBL] [Abstract][Full Text] [Related]
38. Intraoperative irradiation after palliative surgery for locally recurrent rectal cancer.
Suzuki K; Gunderson LL; Devine RM; Weaver AL; Dozois RR; Ilstrup DM; Martenson JA; O'Connell MJ
Cancer; 1995 Feb; 75(4):939-52. PubMed ID: 7531113
[TBL] [Abstract][Full Text] [Related]
39. Complete response after neoadjuvant therapy in rectal cancer: to operate or not to operate?
Dedemadi G; Wexner SD
Dig Dis; 2012; 30 Suppl 2():109-17. PubMed ID: 23207942
[TBL] [Abstract][Full Text] [Related]
40. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
